ResearcherManchester Academic Health Science CentreActive in the last 2 years
Ajith Kumar Siriwardena
Matched on ORCID iD 0000-0001-8004-0560; OpenAlex author ID A5013963848. Sources: OpenAlex.
Their work
- Papers
- 16 (first author 0, last author 4)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 38
2011: 2 papers · 2012: none · 2013: 1 paper · 2014: 1 paper · 2015: 1 paper · 2016: 1 paper · 2017: none · 2018: 2 papers · 2019: none · 2020: 1 paper · 2021: none · 2022: 1 paper · 2023: 1 paper · 2024: 1 paper · 2025: 3 papers · 2026: 1 paper
Papers 16
- Survival After Irreversible Electroporation in Unresectable Locally Advanced Pancreatic Cancer: A Meta-Analysis. Co-author DOI 10.1016/j.jss.2026.08.030↗
- The role of 18F-fluorodeoxyglucose positron emission tomography/computed tomography-derived parameters as prognostic factors in patients undergoing resection f… Co-author DOI 10.1016/j.surg.2025.109271↗
- Development and validation of a diagnostic prediction model for pancreatic ductal adenocarcinoma: VAPOR 1, protocol for a prospective multicentre case-control … Co-author DOI 10.1136/bmjopen-2024-094505↗
- Irreversible electroporation as an intraoperative adjunctive treatment for locally advanced pancreatic cancer after neoadjuvant therapy: An initial clinical ex… Co-author DOI 10.14701/ahbps.24-193↗
- REDISCOVER International Guidelines on the Perioperative Care of Surgical Patients With Borderline-resectable and Locally Advanced Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000006248↗
- Assessing impact, needs and quality-of-life among informal carers of people with pancreatic cancer, a prospective study: the PAN-CARER study protocol. Co-author DOI 10.1136/bmjopen-2022-068178↗
- A fast-track surgery programme leads to timelier treatment and higher resection rates in pancreatic cancer. Co-author DOI 10.1016/j.hpb.2021.10.019↗
- The Influence of Patients' Age on the Outcome of Treatment for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000001486↗
- Irreversible Electroporation in pancreatic ductal adenocarcinoma: Is there a role in conjunction with conventional treatment? Co-author DOI 10.1016/j.ejso.2018.07.047↗
- Evaluation of tumor M2-pyruvate kinase (Tumor M2-PK) as a biomarker for pancreatic cancer. Last author DOI 10.1186/s12957-018-1360-3↗
- Glucose metabolic phenotype of pancreatic cancer. Last author DOI 10.3748/wjg.v22.i12.3471↗
- The Plasma Membrane Calcium Pump in Pancreatic Cancer Cells Exhibiting the Warburg Effect Relies on Glycolytic ATP. Co-author DOI 10.1074/jbc.m115.668707↗
- Pancreatic cancer. Co-author DOI 10.1136/bmj.g6385↗
- Glycolytic ATP fuels the plasma membrane calcium pump critical for pancreatic cancer cell survival. Co-author DOI 10.1074/jbc.m113.502948↗
- Poly(A) RT-PCR measurement of diagnostic genes in pancreatic juice in pancreatic cancer. Last author DOI 10.1038/sj.bjc.6606047↗
- Epidermal growth factor receptor in pancreatic cancer. Last author DOI 10.3390/cancers3021513↗
Closest collaborators
The 25 strongest of 38 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Nicola de Liguori Carino · 6 shared papers, 2018–2026 · strength 1.14
- Paper Irreversible electroporation as an intraoperative adjunctive treatment for locally advanced pancreatic cancer after neo… DOI 10.14701/ahbps.24-193↗
- Paper Survival After Irreversible Electroporation in Unresectable Locally Advanced Pancreatic Cancer: A Meta-Analysis. DOI 10.1016/j.jss.2026.08.030↗
- Paper The role of 18F-fluorodeoxyglucose positron emission tomography/computed tomography-derived parameters as prognostic fa… DOI 10.1016/j.surg.2025.109271↗
- Saurabh Jamdar · 4 shared papers, 2020–2026 · strength 0.72
- Paper Survival After Irreversible Electroporation in Unresectable Locally Advanced Pancreatic Cancer: A Meta-Analysis. DOI 10.1016/j.jss.2026.08.030↗
- Paper The role of 18F-fluorodeoxyglucose positron emission tomography/computed tomography-derived parameters as prognostic fa… DOI 10.1016/j.surg.2025.109271↗
- Paper A fast-track surgery programme leads to timelier treatment and higher resection rates in pancreatic cancer. DOI 10.1016/j.hpb.2021.10.019↗
- Thomas Satyadas · 4 shared papers, 2020–2026 · strength 0.72
- Paper Survival After Irreversible Electroporation in Unresectable Locally Advanced Pancreatic Cancer: A Meta-Analysis. DOI 10.1016/j.jss.2026.08.030↗
- Paper The role of 18F-fluorodeoxyglucose positron emission tomography/computed tomography-derived parameters as prognostic fa… DOI 10.1016/j.surg.2025.109271↗
- Paper A fast-track surgery programme leads to timelier treatment and higher resection rates in pancreatic cancer. DOI 10.1016/j.hpb.2021.10.019↗
- Agastya Patel · 2 shared papers, 2025 · strength 0.54
- Paper Irreversible electroporation as an intraoperative adjunctive treatment for locally advanced pancreatic cancer after neo… DOI 10.14701/ahbps.24-193↗
- Paper The role of 18F-fluorodeoxyglucose positron emission tomography/computed tomography-derived parameters as prognostic fa… DOI 10.1016/j.surg.2025.109271↗
- Francesco Lancellotti · 2 shared papers, 2025 · strength 0.54
- Paper Irreversible electroporation as an intraoperative adjunctive treatment for locally advanced pancreatic cancer after neo… DOI 10.14701/ahbps.24-193↗
- Paper The role of 18F-fluorodeoxyglucose positron emission tomography/computed tomography-derived parameters as prognostic fa… DOI 10.1016/j.surg.2025.109271↗
- Derek A O'Reilly · 3 shared papers, 2018–2022 · strength 0.34
- Paper A fast-track surgery programme leads to timelier treatment and higher resection rates in pancreatic cancer. DOI 10.1016/j.hpb.2021.10.019↗
- Paper The Influence of Patients' Age on the Outcome of Treatment for Pancreatic Ductal Adenocarcinoma. DOI 10.1097/mpa.0000000000001486↗
- Paper Irreversible Electroporation in pancreatic ductal adenocarcinoma: Is there a role in conjunction with conventional trea… DOI 10.1016/j.ejso.2018.07.047↗
- Keith John Roberts · 2 shared papers, 2023–2025 · strength 0.34
- Paper Development and validation of a diagnostic prediction model for pancreatic ductal adenocarcinoma: VAPOR 1, protocol for… DOI 10.1136/bmjopen-2024-094505↗
- Paper Assessing impact, needs and quality-of-life among informal carers of people with pancreatic cancer, a prospective study… DOI 10.1136/bmjopen-2022-068178↗
- Sanjay Pandanaboyana · 2 shared papers, 2023–2025 · strength 0.34
- Paper Development and validation of a diagnostic prediction model for pancreatic ductal adenocarcinoma: VAPOR 1, protocol for… DOI 10.1136/bmjopen-2024-094505↗
- Paper Assessing impact, needs and quality-of-life among informal carers of people with pancreatic cancer, a prospective study… DOI 10.1136/bmjopen-2022-068178↗
- Shahin Hajibandeh · 1 shared paper, 2026 · strength 0.25
- Shahab Hajibandeh · 1 shared paper, 2026 · strength 0.25
- Jenifer Barrie · 1 shared paper, 2025 · strength 0.21
- Juan W. Valle · 2 shared papers, 2018–2020 · strength 0.19
- Mairead Geraldine McNamara · 2 shared papers, 2018–2020 · strength 0.19
- Jason I.E. Bruce · 3 shared papers, 2013–2016 · strength 0.19
- Paper Glucose metabolic phenotype of pancreatic cancer. DOI 10.3748/wjg.v22.i12.3471↗
- Paper Glycolytic ATP fuels the plasma membrane calcium pump critical for pancreatic cancer cell survival. DOI 10.1074/jbc.m113.502948↗
- Paper The Plasma Membrane Calcium Pump in Pancreatic Cancer Cells Exhibiting the Warburg Effect Relies on Glycolytic ATP. DOI 10.1074/jbc.m115.668707↗
- Duncan R.C. Spalding · 1 shared paper, 2025 · strength 0.17
- Samir Pathak · 1 shared paper, 2025 · strength 0.17
- Caoimhe M. Walsh · 1 shared paper, 2025 · strength 0.17
- Bilal A. Al-Sarireh · 1 shared paper, 2025 · strength 0.17
- Zaed Z. R. Hamady · 1 shared paper, 2025 · strength 0.17
- George Bushra Hanna · 1 shared paper, 2025 · strength 0.17
- Stephen P. Pereira · 1 shared paper, 2025 · strength 0.17
- Adam Enver Frampton · 1 shared paper, 2025 · strength 0.17
- Christopher Michael Halloran · 1 shared paper, 2025 · strength 0.17
- Hemant Mahendrakumar Kocher · 1 shared paper, 2025 · strength 0.17
- Eithne Costello · 1 shared paper, 2025 · strength 0.17
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.